Drugs / NCTX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02063594 | Mar → Oct 2014 | — | Marval Pharma Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCTX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02063594 ↗ |
| Known as | PEGylated Liposomal Iodixanol Injection | “NCTX (PEGylated Liposomal Iodixanol Injection)” NCT02063594 ↗ |
| Route | Intravenous | “NCTX (PEGylated Liposomal Iodixanol Injection) administered intravenously to healthy volunteers” NCT02063594 ↗ |